There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - Senate

Short Titles as Introduced

Accountability in Opioid Advertising Act

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.


Actions Overview (1)

Date
09/06/2018Introduced in Senate

All Actions (1)

Date
09/06/2018Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Action By: Senate

Cosponsors (1)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. Gardner, Cory [R-CO]* 09/06/2018

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
Senate Health, Education, Labor, and Pensions09/06/2018 Referred to

No related bill information was received for S.3420.


Latest Summary (1)

There is one summary for S.3420. View summaries

Shown Here:
Introduced in Senate (09/06/2018)

Accountability in Opioid Advertising Act

This bill requires the Food and Drug Administration to prioritize the review of advertising and other promotional materials for drug for serious, life-threatening diseases or conditions or substance use disorders, especially opioids (drugs with effects similar to opium, such as certain pain medications) and drugs used in the treatment of opioid use disorders.